Background Information: Prostate cancer, one of the most common types of cancer, becomes metastatic when it spreads to other parts of the body. Surgery or radiation alone cannot fully treat metastatic prostate cancer, so patients often undergo hormone therapy.  Unfortunately, prostate cancer can develop resistance to hormone therapy and continue to progress despite ongoing treatment.  This stage is known as metastatic-castration-resistant prostate cancer (mCRPC).  Scientists have discovered higher levels of a protein called EZH2 in certain cancers, particularly prostate cancer, which has...

Background Information: Prostate cancer, one of the most common types of cancer, becomes metastatic when it spreads to other parts of the body. Surgery or radiation alone cannot fully treat metastatic prostate cancer, so patients often undergo hormone therapy.  Unfortunately, prostate cancer can develop resistance to hormone therapy and continue to progress despite ongoing treatment.  This stage is known as metastatic–castration–resistant prostate cancer (mCRPC).  Scientists have discovered higher levels of a protein called EZH2 in certain cancers, particularly prostate cancer, which...

Background Information: Prostate cancer is one of the most common types of cancer. It becomes “metastatic” when it spreads to other parts of the body. Surgery or radiation alone cannot fully treat metastatic prostate cancer. Patients often need hormone therapy. When prostate cancer spreads (metastatic) but still responds to medical or surgical treatments, it is called metastatic castration-sensitive prostate cancer (mCSPC). Researchers have found that a protein called EZH2 can be higher in some prostate cancers. High levels of EZH2 may make prostate cancer more likely to resist hormone...